CCM2 antibody (N-Term)

Catalog No. ABIN616006

Product Details anti-CCM2 Antibody

Target: CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Binding Specificity: AA 1-444, N-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CCM2 antibody is un-conjugated

Application: Western Blotting (WB), Immunofluorescence (IF)

Specificity: This antibody detects recombinant Human CCM-2 in Western Blot and native CCM-2 in Immunohistochemistry.

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Protein A Chromatography

Immunogen: Highly pure (> 95%) recombinant Human CCM-2 (Cerebral cavernous malformations 2 protein, aa: Met1-Ala444) from E.coli.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Reconstitution: Restore in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: 5 mM PBS pH 7.2 without preservatives

Preservative: Without preservative

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Prior to reconstitution store at 2-8 °C for one month or dessicated at -20 °C for longer. Following reconstitution store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for CCM2

Target: CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Alternative Name: Malcavernin (CCM2 Products)

Synonyms: C7orf22 antibody, OSM antibody, malcavernin antibody, CCM2 antibody, BC029157 antibody, TUF2 antibody, vtn antibody, zgc:110233 antibody, CCM2 scaffolding protein antibody, cerebral cavernous malformation 2 antibody, malcavernin antibody, CCM2 antibody, Ccm2 antibody, LOC100304744 antibody, ccm2 antibody

Background: Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Familial CCM is caused by mutations in KRIT1 (CCM1) or in malcavernin (CCM2). The roles of the CCM proteins in the pathogenesis of the disorder remain largely unknown. It was shown that the CCM1 gene product, KRIT1, interacts with the CCM2 gene product, malcavernin. Analogous to the established interactions of CCM1 and beta1 integrin with ICAP1, the CCM1/CCM2 association is dependent upon the phosphotyrosine binding (PTB) domain of CCM2. A familial CCM2 missense mutation abrogates the CCM1/CCM2 interaction, suggesting that loss of this interaction may be critical in CCM pathogenesis. CCM2 and ICAP1 bound to CCM1 via their respective PTB domains differentially influence the subcellular localization of CCM1. The data indicate that the genetic heterogeneity observed in familial CCM may reflect mutation of different molecular members of a coordinated signaling complex.Synonyms: C7orf22, CCM2, Cerebral cavernous malformations 2 protein, PP10187

Gene ID: 83605

NCBI Accession: NP_001025006

UniProt: Q9BSQ5

Pathways: Cell-Cell Junction Organization